香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 茲提述錦欣生殖醫療集團有限公司*（「本公司」）日期為2025年9月25日的公告，內容有關 （其中包括）建議採納2025年股份計劃及有條件向本公司董事及高級管理層授出2025年股 份計劃項下的購股權及受限制股份（「該公告」）。除另有界定者外，本公告所用詞彙與該 公告所界定者具有相同涵義。 誠如該公告所披露，一份載有（其中包括）建議採納2025年股份計劃及有條件向董陽先生 授出購股權連同其項下擬進行之其他交易的進一步詳情以及召開股東特別大會的通告的 通函（「該通函」）將寄發予股東。 由於本公司需要額外時間編製及落實載入該通函的若干資料，預期寄發該通函的日期將 推遲至2025年11月11日或之前。 承董事會命 錦欣生殖醫療集團有限公司* 首席執行官、代理首席財務官兼執行董事 Jinxin Fertility Group Limited * 1951 延遲寄發通函 董陽 香港，2025年10月20日 * 僅供識 ...

| 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 費出或涉及的 每股的平均價 | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | (語參聞上述 * 語 | 有投票權股 (日 / 月 / 年) | | | | | | | | 份百分比 | | | | | | | | (%) | | DA20251017E00006 | 量明 500,000(L) | 1101(L) | | HKD 2.5600 | 13,373,318(L) | 0.48(L)15/10/2025 | | 股份代號: | 01951 | | --- | --- | | 上市法國名稱: | 錦欣生殖醫療集團有限公司 | | 日期 (日 / 月 / 年): | 20/09/2025 - 20/10/2025 | 格隆汇10月20日丨根据联交所最新权益披露资料显示，2025年10月15日，锦欣生殖(01951.HK)获执行董事董阳在场内以每股均价2.56港元增持50万股，涉资 约12 ...

锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心设施服务、辅助医疗服务、妇产儿科医疗服务，以 及从事医疗消耗品及设备销售业务。该公司主要在中国及美国提供服务。 证券之星消息，10月17日南向资金增持272.15万股锦欣生殖（01951.HK）。近5个交易日中，获南向资 金增持的有4天，累计净增持2197.45万股。近20个交易日中，获南向资金增持的有15天，累计净增持 6282.75万股。截至目前，南向资金持有锦欣生殖（01951.HK）14.41亿股，占公司已发行普通股的 52.25%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-10-17 | 14.41亿 | 272.15万 | 0.19% | | 2025-10-16 | 14.39 乙 | 383.35万 | 0.27% | | 2025-10 ...

香港联交所最新资料显示，10月15日，执行董事董阳增持锦欣生殖(01951)50万股，每股作价2.56港元， 总金额为128万港元。增持后最新持股数目约为1337.33万股，最新持股比例为0.48%。 ...

智通财经APP获悉，香港联交所最新资料显示，10月15日，执行董事董阳增持锦欣生殖(01951)50万股， 每股作价2.56港元，总金额为128万港元。增持后最新持股数目约为1337.33万股，最新持股比例为 0.48%。 ...

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 3.83 million shares on October 16, 2025, marking a 0.27% increase in total holdings [1] - Over the past five trading days, there have been three days of net increases, totaling 11.73 million shares, while in the last twenty trading days, there were fifteen days of net increases, amounting to 75.63 million shares [1] - As of now, southbound funds hold 1.439 billion shares of Jinxin Reproductive Medicine, representing 52.15% of the company's total issued ordinary shares [1] Summary by Category Trading Activity - On October 16, 2025, total shares held reached 1.439 billion, with an increase of 3.83 million shares [2] - On October 15, 2025, the total shares held were 1.435 billion, with an increase of 11.23 million shares [2] - On October 14, 2025, total shares held were 1.424 billion, with an increase of 5.13 million shares [2] - On October 13, 2025, total shares held were 1.418 billion, with a decrease of 0.94 million shares [2] - On October 3, 2025, total shares held were 1.419 billion, with a decrease of 7.52 million shares [2] Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, obstetrics and pediatrics medical services, and engages in the sale of medical consumables and equipment [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]

Core Viewpoint - Southbound funds have increased their holdings in Jinxin Reproductive Medicine (01951.HK), indicating growing investor confidence in the company [1] Group 1: Shareholding Changes - On October 15, southbound funds increased their holdings by 11.23 million shares, representing a 0.79% change [2] - Over the past 5 trading days, there were 2 days of net increases, totaling 1.65 million shares [1] - In the last 20 trading days, there were 15 days of net increases, amounting to 74.79 million shares [1] Group 2: Current Shareholding Status - As of now, southbound funds hold 1.435 billion shares of Jinxin Reproductive Medicine, accounting for 52.02% of the company's total issued ordinary shares [1]

Core Insights - Southbound funds increased their holdings in Jinxin Fertility (01951.HK) by 5.1255 million shares on October 14, 2025, marking a 0.36% increase in total shares held [1][2] - Over the past 20 trading days, Jinxin Fertility experienced net increases in holdings for 14 days, totaling 62.0595 million shares [1][2] - As of now, southbound funds hold 1.424 billion shares of Jinxin Fertility, representing 51.61% of the company's total issued ordinary shares [1][2] Trading Data Summary - On October 14, 2025, total shares held reached 1.424 billion with an increase of 5.1255 million shares [2] - On October 13, 2025, total shares held were 1.418 billion, reflecting a decrease of 936,500 shares [2] - On October 3, 2025, total shares held were 1.419 billion, with a decrease of 7.5195 million shares [2] - On October 2, 2025, total shares held were 1.427 billion, showing a decrease of 6.2525 million shares [2] - On September 30, 2025, total shares held were 1.433 billion, with an increase of 9.5175 million shares [2] Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, obstetrics and pediatrics medical services, and engages in the sale of medical consumables and equipment [2] - Jinxin Fertility operates mainly in China and the United States [2]

Core Viewpoint - The company's short-term performance is under pressure due to multiple factors, but overall revenue is expected to stabilize in the second half of 2025, with a potential narrowing of profit decline [1][4] Financial Performance - In the first half of 2025, the company reported revenue of 1.289 billion yuan, a year-on-year decrease of 10.7%, and a net loss attributable to shareholders of 1.044 billion yuan, compared to a net profit of 190 million yuan in the same period last year [1][2] - Adjusted net profit was 82 million yuan, down 68.3% year-on-year, with earnings per share (EPS) at -0.39 yuan [1][2] Regional Performance - Chengdu's medical service revenue was approximately 768 million yuan, with the number of egg retrieval cycles decreasing by 6.1% to 7,111 due to an increase in IUI cycle patients [2] - The Greater Bay Area generated 206 million yuan in medical service revenue, with egg retrieval cycles down 16.0% to 2,539, influenced by changes in clinical procedures [2] - Revenue from Kunming and Wuhan was 131 million yuan, with egg retrieval cycles down 3.5% to 2,059, mainly due to hospital renovations [2] - Overseas medical service revenue was 405 million yuan, with egg retrieval cycles down 8.9% to 2,058, but revenue remained stable year-on-year [2] Market and Policy Environment - Since 2021, a series of policies encouraging childbirth have been introduced in China, with all 31 provinces and regions including assisted reproduction in medical insurance by March 2025, expected to enhance technology penetration [3] - The delay of California's commercial insurance law until January 2026 is anticipated to drive growth in treatment cycles in the U.S. market over the next 3-5 years [3] Profitability and Cost Management - The company's overall gross margin for the first half of 2025 was 30.4%, a decrease of 10 percentage points year-on-year, primarily due to the increased proportion of lower-margin IUI cycles and price pressures from medical insurance [3] - Sales and distribution expenses decreased by 14.5% to 74 million yuan, while R&D expenses fell by 17.4% to 9 million yuan [3] Future Outlook - The company is expected to benefit from the gradual release of domestic fertility support policy dividends and the continuous improvement of assisted reproduction penetration rates [5] - Revenue projections for 2025-2027 are 2.650 billion, 2.875 billion, and 3.132 billion yuan, with year-on-year growth rates of -5.76%, 8.52%, and 8.91% respectively [5]

Core Viewpoint - Southbound funds have reduced their holdings in Jinxin Fertility (01951.HK) by 936,500 shares on October 13, indicating a trend of net selling over recent trading days [1] Group 1: Shareholding Changes - In the last five trading days, southbound funds have reduced their holdings on three occasions, with a total net reduction of 2,049,500 shares [1] - Over the past twenty trading days, there have been thirteen days of net increases in holdings, totaling 56,847,000 shares [1] - As of now, southbound funds hold 1.418 billion shares of Jinxin Fertility, representing 51.42% of the company's total issued ordinary shares [1] Group 2: Recent Trading Data - On October 13, 2025, the total shareholding was 1.418 billion shares, with a decrease of 936,500 shares, reflecting a change of -0.07% [2] - On October 3, 2025, the total shareholding was 1.419 billion shares, with a decrease of 7,519,500 shares, reflecting a change of -0.53% [2] - On October 2, 2025, the total shareholding was 1.427 billion shares, with a decrease of 625,250 shares, reflecting a change of -0.44% [2] - On September 30, 2025, the total shareholding was 1.433 billion shares, with an increase of 9,517,500 shares, reflecting a change of +0.67% [2] - On September 29, 2025, the total shareholding was 1.424 billion shares, with an increase of 3,141,500 shares, reflecting a change of +0.22% [2] Group 3: Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment [2] - The company's services are mainly provided in China and the United States [2]